Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
ESMO-BC 2024 | Berlin, Germany
May 15 - 17, 2024
Poster
TACTIVE-K: Phase 1b/2 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With PF-07220060, a Cyclin-Dependent Kinase 4 Inhibitor, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast CancerAUA 2024 | San Antonio, TX
May 3 - 6, 2024
Poster
ARV-766, a PROTAC Androgen Receptor Degrader, Combined With Abiraterone in Novel Hormonal Agent–Naïve Metastatic Prostate Cancer: Phase 1 Cohort (Part C) of a Phase 1/2 StudyAACR 2024 | San Diego, CA
Apr 5 - 10, 2024
Presentation
The Discovery of ARV-393, a Potent, Orally Bioavailable BCL6-Targeting PROTAC® for the Treatment of NHLASCPT 2024 | Colorado Springs, CO
Mar 27 - 29, 2024
Poster
The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader in Healthy Adult ParticipantsASCPT 2024 | Colorado Springs, CO
Mar 27 - 29, 2024
Poster
The Effect of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, on Dabigatran Pharmacokinetics in Healthy Adult ParticipantsASCPT 2024 | Colorado Springs, CO
Mar 27 - 29, 2024
Poster
Evaluation of the Effect of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, on Rosuvastatin Pharmacokinetics in Healthy Adult ParticipantsASCPT 2024 | Colorado Springs, CO
Mar 27 - 29, 2024
Poster
Drug-Drug Interaction Study of the PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader Bavdegalutamide in Combination With the P-glycoprotein Substrate Fexofenadine in Healthy Male VolunteersASCO-GU 2024 | San Francisco, CA
Jan 25 - 27, 2024
Poster
Real-World Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Tumors Harboring Androgen Receptor (AR) Ligand-Binding Domain (LBD) MutationsSABCS 2023 | San Antonio, TX
Dec 5 - 9, 2023